|
JP2013067662A
|
|
Process for preparing a2a-adenosine receptor agonist and polymorph of the same
|
|
JP2011098990A
|
|
Myocardial perfusion imaging using adenosine receptor agonist
|
|
US2011039799A1
|
|
A1 adenosine receptor agonist polymorphs
|
|
US2010130436A1
|
|
Co-administration of ranolazine and cardiac glycosides
|
|
WO2010056865A1
|
|
Quinoline derivatives as ion channel modulators
|
|
ZA200907778B
|
|
Method of treating diabetes
|
|
TW201028371A
|
|
Fused heterocyclic compounds as ion channel modulators
|
|
US2010113514A1
|
|
Fused heterocyclic compounds as ion channel modulators
|
|
US2010113461A1
|
|
Substituted heterocyclic compounds
|
|
US2010267752A1
|
|
3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
|
US2010267748A1
|
|
HETEROCYCLIC COMPOUNDS USEFUL AS STEAROYL CoA DESATURASE INHIBITORS
|
|
EP2200615A1
|
|
A3 adenosine receptor antagonists
|
|
US2008255130A1
|
|
Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
|
|
KR20100130589A
|
|
Aldh-2 inhibitors in the treatment of addiction
|
|
AU2007278877A1
|
|
ALDH-2 inhibitors in the treatment of addiction
|
|
SG173924A1
|
|
Myocardial perfusion imaging using adenosine receptor agonists
|
|
AU2004200192A1
|
|
Purine inhibitors of cyclin dependent kinase 2 and 1k-Aa
|
|
AU2003303676A1
|
|
Substituted heterocyclic compounds
|
|
AU2003300827A1
|
|
Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
|
|
US2004064039A1
|
|
Myocardial perfusion imaging method
|
